Cargando…

Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis

PURPOSE: Preoperative hypertrophy induction of future liver remnant (FLR) reduces the risk of postoperative liver insufficiency after partial hepatectomy. One of the most commonly used methods to induce hypertrophy of FLR is portal vein embolization (PVE). Recent studies have shown that transarteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Nebelung, Heiner, Wolf, Thomas, Bund, Sebastian, Radosa, Christoph Georg, Plodeck, Verena, Grosche-Schlee, Sabine, Riediger, Carina, Hoffmann, Ralf-Thorsten, Kühn, Jens-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286933/
https://www.ncbi.nlm.nih.gov/pubmed/33779787
http://dx.doi.org/10.1007/s00261-021-03048-1
_version_ 1783723814839910400
author Nebelung, Heiner
Wolf, Thomas
Bund, Sebastian
Radosa, Christoph Georg
Plodeck, Verena
Grosche-Schlee, Sabine
Riediger, Carina
Hoffmann, Ralf-Thorsten
Kühn, Jens-Peter
author_facet Nebelung, Heiner
Wolf, Thomas
Bund, Sebastian
Radosa, Christoph Georg
Plodeck, Verena
Grosche-Schlee, Sabine
Riediger, Carina
Hoffmann, Ralf-Thorsten
Kühn, Jens-Peter
author_sort Nebelung, Heiner
collection PubMed
description PURPOSE: Preoperative hypertrophy induction of future liver remnant (FLR) reduces the risk of postoperative liver insufficiency after partial hepatectomy. One of the most commonly used methods to induce hypertrophy of FLR is portal vein embolization (PVE). Recent studies have shown that transarterial radioembolization (TARE) also induces hypertrophy of the contralateral liver lobe. The aim of our study was to evaluate contralateral hypertrophy after TARE versus after PVE taking into account the effect of cirrhosis. METHODS: Forty-nine patients undergoing PVE before hemihepatectomy and 24 patients with TARE as palliative treatment for liver malignancy were retrospectively included. Semi-automated volumetry of the FLR/contralateral liver lobe before and after intervention (20 to 65 days) was performed on CT or MRI, and the relative increase in volume was calculated. Cirrhosis was evaluated independently by two radiologists on CT/MRI, and interrater reliability was calculated. RESULTS: Hypertrophy after PVE was significantly more pronounced than after TARE (25.3% vs. 7.4%; p < 0.001). In the subgroup of patients without cirrhosis, the difference was also statistically significant (25.9% vs. 8.6%; p = 0.002), whereas in patients with cirrhosis, the difference was not statistically significant (18.2% vs. 7.4%; p = 0.212). After PVE, hypertrophy in patients without cirrhosis was more pronounced than in patients with cirrhosis (25.9% vs. 18.2%; p = 0.203), while after TARE, hypertrophy was comparable in patients with and without cirrhosis (7.4% vs. 8.6%; p = 0.928). CONCLUSION: TARE induces less pronounced hypertrophy of the FLR compared to PVE. Cirrhosis seems to be less of a limiting factor for hypertrophy after TARE, compared to PVE. GRAPHIC ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8286933
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-82869332021-07-20 Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis Nebelung, Heiner Wolf, Thomas Bund, Sebastian Radosa, Christoph Georg Plodeck, Verena Grosche-Schlee, Sabine Riediger, Carina Hoffmann, Ralf-Thorsten Kühn, Jens-Peter Abdom Radiol (NY) Interventional Radiology PURPOSE: Preoperative hypertrophy induction of future liver remnant (FLR) reduces the risk of postoperative liver insufficiency after partial hepatectomy. One of the most commonly used methods to induce hypertrophy of FLR is portal vein embolization (PVE). Recent studies have shown that transarterial radioembolization (TARE) also induces hypertrophy of the contralateral liver lobe. The aim of our study was to evaluate contralateral hypertrophy after TARE versus after PVE taking into account the effect of cirrhosis. METHODS: Forty-nine patients undergoing PVE before hemihepatectomy and 24 patients with TARE as palliative treatment for liver malignancy were retrospectively included. Semi-automated volumetry of the FLR/contralateral liver lobe before and after intervention (20 to 65 days) was performed on CT or MRI, and the relative increase in volume was calculated. Cirrhosis was evaluated independently by two radiologists on CT/MRI, and interrater reliability was calculated. RESULTS: Hypertrophy after PVE was significantly more pronounced than after TARE (25.3% vs. 7.4%; p < 0.001). In the subgroup of patients without cirrhosis, the difference was also statistically significant (25.9% vs. 8.6%; p = 0.002), whereas in patients with cirrhosis, the difference was not statistically significant (18.2% vs. 7.4%; p = 0.212). After PVE, hypertrophy in patients without cirrhosis was more pronounced than in patients with cirrhosis (25.9% vs. 18.2%; p = 0.203), while after TARE, hypertrophy was comparable in patients with and without cirrhosis (7.4% vs. 8.6%; p = 0.928). CONCLUSION: TARE induces less pronounced hypertrophy of the FLR compared to PVE. Cirrhosis seems to be less of a limiting factor for hypertrophy after TARE, compared to PVE. GRAPHIC ABSTRACT: [Image: see text] Springer US 2021-03-29 2021 /pmc/articles/PMC8286933/ /pubmed/33779787 http://dx.doi.org/10.1007/s00261-021-03048-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Interventional Radiology
Nebelung, Heiner
Wolf, Thomas
Bund, Sebastian
Radosa, Christoph Georg
Plodeck, Verena
Grosche-Schlee, Sabine
Riediger, Carina
Hoffmann, Ralf-Thorsten
Kühn, Jens-Peter
Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis
title Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis
title_full Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis
title_fullStr Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis
title_full_unstemmed Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis
title_short Radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis
title_sort radioembolization versus portal vein embolization for contralateral liver lobe hypertrophy: effect of cirrhosis
topic Interventional Radiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8286933/
https://www.ncbi.nlm.nih.gov/pubmed/33779787
http://dx.doi.org/10.1007/s00261-021-03048-1
work_keys_str_mv AT nebelungheiner radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT wolfthomas radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT bundsebastian radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT radosachristophgeorg radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT plodeckverena radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT groscheschleesabine radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT riedigercarina radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT hoffmannralfthorsten radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis
AT kuhnjenspeter radioembolizationversusportalveinembolizationforcontralateralliverlobehypertrophyeffectofcirrhosis